{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:34:52Z","timestamp":1791390892088,"version":"4.3.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2159,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,2,12]],"date-time":"2017-02-12T00:00:00Z","timestamp":1486857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"TherapeuticsMD"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, but most symptomatic women do not receive prescription therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To evaluate postmenopausal women's perceptions of VVA and treatment options for symptoms in the Women's EMPOWER survey.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Rose Research firm conducted an internet survey of female consumers provided by Lightspeed Global Market Insite. Women at least 45 years of age who reported symptoms of VVA and residing in the United States were recruited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Survey results were compiled and analyzed by all women and by treatment subgroups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Respondents (N\u00a0= 1,858) had a median age of 58 years (range\u00a0= 45\u201390). Only 7% currently used prescribed VVA therapies (local estrogen therapies or oral selective estrogen receptor modulators), whereas 18% were former users of prescribed VVA therapies, 25% used over-the-counter treatments, and 50% had never used any treatment. Many women (81%) were not aware of VVA or that it is a medical condition. Most never users (72%) had never discussed their symptoms with a health care professional (HCP). The main reason for women not to discuss their symptoms with an HCP was that they believed that VVA was just a natural part of aging and something to live with. When women spoke to an HCP about their symptoms, most (85%) initiated the discussion. Preferred sources of information were written material from the HCP's office (46%) or questionnaires to fill out before seeing the HCP (41%).The most negative attributes of hormonal products were perceived risk of systemic absorption, messiness of local creams, and the need to reuse an applicator. Overall, HCPs only recommended vaginal estrogen therapy to 23% and oral hormone therapies to 18% of women. When using vaginal estrogen therapy, less than half of women adhered to and complied with posology; only 33% to 51% of women were very to extremely satisfied with their efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The Women's EMPOWER survey showed that VVA continues to be an under-recognized and under-treated condition, despite recent educational initiatives. A disconnect in education, communication, and information between HCPs and their menopausal patients remains prevalent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2017.01.010","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T15:58:35Z","timestamp":1487001515000},"page":"413-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"title":["The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment"],"prefix":"10.1093","volume":"14","author":[{"given":"Sheryl A.","family":"Kingsberg","sequence":"first","affiliation":[{"name":"University Hospitals Cleveland Medical Center \u00a0 , Cleveland, OH , USA"},{"name":"MacDonald Women's Hospital \u00a0 , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Krychman","sequence":"additional","affiliation":[{"name":"Southern California Center for Sexual Health and Survivorship Medicine Inc , Newport Beach, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelli","family":"Graham","sequence":"additional","affiliation":[{"name":"TherapeuticsMD , Boca Raton, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bernick","sequence":"additional","affiliation":[{"name":"TherapeuticsMD , Boca Raton, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[{"name":"TherapeuticsMD , Boca Raton, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,12]]},"reference":[{"key":"2023011111045922100_bib1","article-title":"Annual estimates of the resident population for selected age groups by sex: April 1, 2010 to July 1, 2015","author":"US Census Bureau"},{"key":"2023011111045922100_bib2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/aje\/kwj282","article-title":"From menarche to menopause: trends among US Women born from 1912 to 1969","volume":"164","author":"Nichols","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2023011111045922100_bib3","first-page":"2133","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women","volume":"6","author":"Santoro","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"2023011111045922100_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.maturitas.2010.08.001","article-title":"Women's voices in the menopause: results from an international survey on vaginal atrophy","volume":"67","author":"Nappi","year":"2010","journal-title":"Maturitas"},{"key":"2023011111045922100_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal health: insights, views & attitudes (VIVA)\u2014results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"2023011111045922100_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2023011111045922100_bib7","first-page":"1790","article-title":"Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"2023011111045922100_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13697137.2015.1107039","article-title":"Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey","volume":"19","author":"Nappi","year":"2016","journal-title":"Climacteric"},{"key":"2023011111045922100_bib9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/GME.0b013e318287342d","article-title":"Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"2023011111045922100_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1258\/175404507780796424","article-title":"Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey","volume":"13","author":"Cumming","year":"2007","journal-title":"Menopause Int"},{"key":"2023011111045922100_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IJWH.S44579","article-title":"Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy","volume":"5","author":"Parish","year":"2013","journal-title":"Int J Womens Health"},{"key":"2023011111045922100_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/GME.0000000000000880","article-title":"Visual improvements in vaginal mucosa correlate with symptoms of VVA: Data from a double-blind, placebo-controlled trial","author":"Simon","year":"2017","journal-title":"Menopause"},{"key":"2023011111045922100_bib13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"2023011111045922100_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"Management of menopausal symptoms. Practice bulletin no. 141. American College of Obstetricians and Gynecologists","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"2023011111045922100_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/GME.0b013e318295236f","article-title":"Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners","volume":"21","author":"Simon","year":"2014","journal-title":"Menopause"},{"key":"2023011111045922100_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of the North American Menopause Society","volume":"19","author":"North American Menopause Society","year":"2012","journal-title":"Menopause"},{"key":"2023011111045922100_bib17","article-title":"Customer satisfaction surveys & research: how to measure CSAT","author":"B2B International"},{"key":"2023011111045922100_bib18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/GME.0000000000000316","article-title":"Why the product labeling for low-dose vaginal estrogen should be changed","volume":"21","author":"Manson","year":"2014","journal-title":"Menopause"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517300589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609517300589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/3\/413\/48526096\/jsm_14_3_413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/14\/3\/413\/48526096\/jsm_14_3_413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:42:24Z","timestamp":1673448144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/14\/3\/413\/6973596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,12]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,2,12]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.01.010","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2017,2,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Women's EMPOWER Survey: Identifying Women's Perceptions on Vulvar and Vaginal Atrophy and Its Treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2017.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.","name":"copyright","label":"Copyright"}]}}